The use of ECT and MST in treating depression

Department of Psychiatry, University of Oxford, Oxford, UK.
International Review of Psychiatry (Impact Factor: 1.8). 10/2011; 23(5):400-12. DOI: 10.3109/09540261.2011.614223
Source: PubMed


Electroconvulsive therapy (ECT) has been used clinically since 1938. Its most common use is in the treatment of depression: first line treatment where rapid recovery is a priority, but more frequently as an effective treatment for patients who do not respond to pharmacological and psychological approaches. Whilst it is widely hailed as an effective treatment, concerns about its effect on cognition remain. The development of magnetic seizure therapy (MST) over the past decade has attempted to devise a therapy with comparable efficacy to ECT, but without the associated cognitive side effects. The rationale for this is that MST uses magnetic fields to induce seizures in the cortex, without electrical stimulation of brain structures involved with memory. MST has been used successfully in the treatment of depression, yet there is a dearth of literature in comparison with ECT. We present a systematic review of the literature on ECT (from 2009-2011) and MST (from 2001-2011).

58 Reads
  • Source
    • "These studies underscore the idea that the anti-depressive effects of ECT might become significant after a few convulsions. During the last decade the efficacy of trans-cranial magnetic seizure therapy, deep brain and vagus stimulation have been explored , but their clinical efficacy has still to be established [22] [23] [26]. Their beneficial responses appear to be slow. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The hypothesis defended here is that the process of mood-normalizing transitions fails in a significant proportion of patients suffering from major depressive disorder. Such a failure is largely unrelated to the psychological content. Evidence for the hypothesis is provided by the highly variable and unpredictable time-courses of the depressive episodes. The main supporting observations are: 1) mood transitions within minutes or days have been reported during deep brain stimulation, naps after sleep deprivation and bipolar mood disorders; 2) sleep deprivation, electroconvulsive treatment and experimental drugs (e.g. ketamine) may facilitate mood transitions in major depressive disorder within hours or a few days; 3) epidemiological and clinical studies show that the time-to-recovery from major depressive disorder can be described with decay models implying very short depressive episodes; 4) lack of relationship between the length of depression and recovery episodes in recurrent depression; 5) mood fluctuations predict later therapeutic success in major depressive disorder. We discuss some recent models aimed to describe random mood transitions. The observations together suggest that the mood transitions have a wide variety of apparently unrelated causes. We suggest that the mechanism of mood transition is compromised in major depressive disorder, which has to be recognized in diagnostic systems.
    Medical Hypotheses 05/2014; 82(5). DOI:10.1016/j.mehy.2014.02.015 · 1.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the effects of microcurrent cranial electrical stimulation (CES) therapy on activity in pain processing brain regions. A randomized, controlled, three-group, double-blind pilot study. Persons with physician-diagnosed fibromyalgia. Active CES device, sham device, and usual care alone. Those individuals using the active device had a greater decrease in average pain (P = .023) than individuals using the sham device or receiving usual care alone over time. Preliminary analyses of the functional magnetic resonance imaging data on a subset of six participants from each of the two device groups show that individuals using an active CES device had a decrease in activation in the pain processing regions of the brain compared to those using a sham device. The observed decrease in activation in the pain processing regions may indicate a decrease in neural activity in these regions that may be related to decreased pain. This is the first randomized, controlled trial of CES in patients diagnosed with fibromyalgia to report functional magnetic resonance imaging data.
    EXPLORE The Journal of Science and Healing 01/2013; 9(1):32-40. DOI:10.1016/j.explore.2012.10.006 · 1.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immer noch spricht nur jeder zweite Patient ausreichend auf eine erste antidepressive Therapie an. Dies trotz eines umfangreichen Therapieangebots. Eine Leitlinien-basierte Behandlung der unipolaren Depression kann zu einer deutlichen Erhöhung der Response- und Remissionsraten führen. Die im Artikel dargestellten Empfehlungen basieren auf den Behandlungsempfehlungen der Schweizerischen Gesellschaft für Psychiatrie und Psychotherapie (SGPP), der Schweizerischen Gesellschaft für Angst und Depression (SGAD) sowie der Schweizerischen Gesellschaft für Biologische Psychiatrie (SGBP).
Show more